The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carbapenem Resistant Enterobacteriaceae Bloodstream Infection
Carbapenem-resistant Enterobacteriaceae
About this trial
This is an interventional treatment trial for Carbapenem-resistant Enterobacteriaceae focused on measuring Tigecycline, Population pharmacokinetics, pharmacokinetics-pharmacodynamics index, bloodstream infection, CRE, Carbapenem-resistant Enterobacteriaceae
Eligibility Criteria
Inclusion Criteria: 20 years and older who were admitted at Phramongkutklao Hospital Patients who were diagnosed bloodstream infection with CRE and who were sepsis or septic shock Patients who received tigecycline loading dose 200 mg infusion for 1 hour and following maintenance dose 100 mg every 12 h infusion for 1 hour at least 48 hours and grant for blood collection Exclusion Criteria: Pregnancy or Breastfeeding Patients who cannot tolerant to the toxicity of tigecycline for example hypersensitivity to tigecycline or any component of the formulation Patients who were infected with more than one isolated in blood culture at the same time
Sites / Locations
- Phramongkutklao HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Intervention group
Patients who were infected caused by CRE bloodstream infection and were treated with tigecycline. Blood samples were collected.